LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Listă Acțiuni・Natera Inc

Natera Inc

Închisă

SectorSănătate

200.55 -1.26

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

197.57

Maxim

203.77

Indicatori cheie
By Trading Economics
Venit	-132M -85M
Vânzări	31M 697M
EPS	-0.6
Marjă de profit	-12.214
Angajați	6,135
EBITDA	-38M -73M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+28.74% upside

Dividende
By Dow Jones
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-2.5B 28B
Deschiderea anterioară	201.81
Închiderea anterioară	200.55

Sentimentul știrilor

By Acuity

54%

46%

279 / 345 Clasament în Healthcare

Natera Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

25 mai 2026, 08:24 UTC

Principalele dinamici ale pieței

Achiziții, Fuziuni, Preluări

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 mai 2026, 21:22 UTC

Câștiguri

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 mai 2026, 20:50 UTC

Market Talk

Câștiguri

Basic Materials Roundup: Market Talk

25 mai 2026, 16:20 UTC

Market Talk

Câștiguri

Basic Materials Roundup: Market Talk

25 mai 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 mai 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 mai 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 mai 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 mai 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 mai 2026, 12:56 UTC

Market Talk

Câștiguri

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 mai 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 mai 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25 mai 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 mai 2026, 12:10 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Delivery Hero's Assets Look Strategic -- Market Talk

25 mai 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 mai 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 mai 2026, 10:05 UTC

Câștiguri

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 mai 2026, 10:04 UTC

Câștiguri

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 mai 2026, 10:03 UTC

Câștiguri

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 mai 2026, 10:02 UTC

Câștiguri

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 mai 2026, 10:01 UTC

Câștiguri

Tenaga Nasional 1Q Net Up 3.7% on Year

25 mai 2026, 10:00 UTC

Câștiguri

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 mai 2026, 09:56 UTC

Câștiguri

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 mai 2026, 09:56 UTC

Câștiguri

Tenaga Nasional 1Q EPS MYR0.1883

25 mai 2026, 09:56 UTC

Câștiguri

Tenaga Nasional 1Q Rev MYR17.1B

25 mai 2026, 09:56 UTC

Câștiguri

Tenaga Nasional 1Q Net MYR1.1B

25 mai 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 mai 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25 mai 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 mai 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Comparație

Modificare preț

Natera Inc Așteptări

Obiectiv de preț

By TipRanks

28.74% sus

Prognoză pe 12 luni

Medie 261.58 USD 28.74%

Maxim 300 USD

Minim 199.14 USD

În baza a 15 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNatera Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

15 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 15 analiști care au acordat evaluări ale acțiunilor Natera Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

279 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.